Three analysts polled by Capital IQ expected GAAP EPS of $0.05.
Revenue for the quarter ended March 31 was $32.3 million, compared with $28.4 million a year ago. Three analysts polled by Capital IQ projected $31.1 million.
Looking ahead, the medical-device supplier said it expects Q2 revenue of $32.3 million to $33.1 million. Two analysts polled by Capital IQ project $31.5 million.
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|